BerGenBio announces ACCORD2 phase II study of bemcentinib in combo with SoC therapy in hospitalized Covid-19 patients meets primary efficacy endpoint

27. April 2022 NEWS

BerGenBio announces ACCORD2 phase II study of bemcentinib in combo with SoC therapy in hospitalized Covid-19 patients meets primary efficacy endpoint: Bergen, Norway Wednesday, Ap …
(Orginal – Story lesen…)

Tags: arm snapdragon snapdragon 835

You may also like...